Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Galmed Pharmaceuticals Ltd.

Headquarters: Tel Aviv, Israel
Year Founded: 2000
Status: Public
Industry Sector: HealthTechnology
CEO: Allen Baharaff
Number Of Employees: 8
Enterprise Value: $-11,457,860
PE Ratio: -0.14
Exchange/Ticker 1: NASDAQ:GLMD
Exchange/Ticker 2: N/A
Latest Market Cap: $2,861,500

BioCentury | Nov 3, 2018
Product Development

New partners for NASH

New NASH targets and combinations will be in the spotlight at this year’s AASLD
BioCentury | Jun 22, 2018
Financial News

Galmed raises $75M follow-on

BioCentury | Jun 20, 2018
Financial News

Galmed raises $75M follow-on

BioCentury | Jun 14, 2018
Clinical News

After NASH readout, Galmed looks to Phase III

BioCentury | Jun 12, 2018
Clinical News

After NASH readout, Galmed looks to Phase III

BioCentury | Feb 14, 2018
Clinical News

Galmed falls on Phase IIa HIV-associated NAFLD miss

BioCentury | Oct 3, 2016
Financial News

Galmed Pharmaceuticals completes private placement

BioCentury | Sep 9, 2016
Company News

Management tracks

Items per page:
1 - 10 of 31